China Resources Double-Crane Pharmaceutical ,Ltd. Profit Margin

China Resources Double-Crane Pharmaceutical ,Ltd. (600062.SS) currently reports a profit margin of 14.54% as of September 2026. That compares with 14.44% in the prior-year period — up 0.7% year over year. That is above the sector sector average of 13.78%. Use the charts on this page to explore China Resources Double-Crane Pharmaceutical ,Ltd.'s profit margin history and peer comparisons.

China Resources Double-Crane Pharmaceutical ,Ltd.'s profit margin increased from 14.44% to 14.54% — a 0.7% year-over-year increase (period ending September 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

China Resources Double-Crane Pharmaceutical ,Ltd.'s profit margin of 14.54% is higher than the its sector sector average of 13.78%. That is roughly 5.6% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but China Resources Double-Crane Pharmaceutical ,Ltd.'s current 14.54% should be judged against industry norms (sector average: 13.78%) and against 600062.SS's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of 14.54%, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is 13.78%. From there, open related valuation or income-statement pages for China Resources Double-Crane Pharmaceutical ,Ltd., and consider following 600062.SS for alerts when major investors trade the stock.